Promoting equity and evidence in drug policy in the midst and wake of COVID-19
This brief is submitted by the Canadian HIV/AIDS Legal Network (Special Consultative Status) on behalf of the Canadian Civil Society Working Group on United Nations Drug Policy. It should be considered alongside the submission by the Canadian Centre on Substance Use and Addiction, which also makes recommendations related to recognizing the impacts of COVID-19 on people who use drugs and to safe supply.
The following recommendations highlight priority areas in which Member State s can play a leadership role in advancing evidence-informed, inclusive and effective drug policy that is grounded in a public health approach and in alignment with complementary United Nations initiatives, including the promotion of human rights and achievement of the Sustainable Development Goals.
Read the full submission here: